NED Biosystems™ is a clinical-stage biotech company developing innovative treatments unlike most available today. We begin with a focus on patients and their families. NED seeks to dramatically improve patients’ outcomes with therapies that lack the toxicity and side effects of today’s treatments, allowing patients a high quality of life.

An Unmet Global Need for Cancer Treatment

Cancer is a critical health problem in the U.S., where it is the second leading cause of death and accounts for about 600,000 deaths each year. Yet, the devastating impact of cancer is even worse in the developing world where:

  • Cancer kills 50% more people in developing countries than HIV, malaria, and TB combined.
  • Africa, Asia, Central and South America together account for 70% of the world’s cancer deaths.¹
  • 80% of cancer patients in Africa are diagnosed at advanced stages, with pain relief their only treatment.
  • In developing countries, few cancer patients ever receive treatment because most of today’s cancer drugs require sophisticated medical infrastructure and require cold chain management (refrigeration) during shipping and storage.

NED-170 pledges to fill this unmet need in developing countries. NED-170 will not require infusion centers or other “traditional” cancer medical infrastructures. We believe NED-170 will be a viable therapy for developing world patients suffering from a broad range of cancers. As part of our corporate mission, NED is committed to supplying NED-170 to patients in the developing world.

¹World Health Organization

A Multi-Pronged Approach to a Global Pandemic

The COVID-19 pandemic has gripped America and the world in a medical, social, and economic crises, leading to severe economic slowdown globally and ushering in lockdowns across most U.S. states and >185 countries.

Most experts suggest that the earliest an approved vaccine may become widely available is mid-2021, approximately 12-18 months after Sars-CoV-2 first emerged. So far seven coronaviruses already infect human beings and, like the common cold, we have yet to develop a vaccine for any of these. Without a vaccine or treatments in place, our health remains at risk as economies reopen.

“A second wave of infections is inevitable.” -Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases

  • In the United States, approximately 2% of confirmed COVID-19 cases have died. By comparison, seasonal flu generally kills far fewer than 1% of those infected.²
  • Over 171.3 million people are confirmed infected with COVID-19 worldwide.²
  • Over 3.3 million deaths globally are attributed to COVID-19; over 595,600  in the U.S.²
  • Over 108,450 citizens of New York City have been hospitalized with COVID-19.³

As economic hardship puts pressure on businesses to reopen, a prophylactic treatment is needed to ensure the safety of our communities.

We believe NED-260, an oral investigational product, has the prospect to provide two essential solutions:

  • to protect against viral infection and cellular entry
  • to halt disease progression in patients and prevent deaths

We at NED Biosystems believe NED-260 may offer vitally needed solutions to provide America and the world a way out of quarantine and isolation.

²John Hopkins University, as of June 2, 2021
³New York State Department of Health, as of June 2, 2021